Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
about
Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab.Both cladribine and alemtuzumab may effect MS via B-cell depletionMemory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.Monoclonal Antibodies in Preclinical EAE Models of Multiple Sclerosis: A Systematic Review.Alemtuzumab in the long-term treatment of relapsing-remitting multiple sclerosis: an update on the clinical trial evidence and data from the real world.Alemtuzumab depletion failure can occur in multiple sclerosis.Decreased platelet number in multiple sclerosis during alemtuzumab infusion: a common, transient and clinically silent phenomenon.Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis
P2860
Q36399264-2DC741D1-1241-4B21-86F0-98CC1D3E0B9DQ38720045-84BC9871-0D37-47BD-A9C5-DA1C767A5D51Q39119839-DF01DDEE-4E22-466F-BDFC-D56956B7B315Q41660408-68861D19-AA53-4E8D-8027-E3ED3AA93A1EQ42361890-93AD4B04-A5B2-4B54-8AE9-12AF336DCB2BQ48106234-2900F54A-87C0-4B6E-A8DA-7C9FF1F31ADCQ49168957-8E3826CF-0434-4F70-AD73-1AE21ADE6174Q59129976-CA52DE27-F63E-43C2-A7B8-8E5D3630ED85
P2860
Depletion of CD52-positive cells inhibits the development of central nervous system autoimmune disease, but deletes an immune-tolerance promoting CD8 T-cell population. Implications for secondary autoimmunity of alemtuzumab in multiple sclerosis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 07 December 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@en
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@nl
type
label
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@en
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@nl
prefLabel
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@en
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@nl
P2093
P2860
P356
P1433
P1476
Depletion of CD52-positive cel ...... tuzumab in multiple sclerosis.
@en
P2093
David Baker
Gareth Pryce
Stephanie von Kutzleben
P2860
P304
P356
10.1111/IMM.12696
P577
2016-12-07T00:00:00Z